Hypertension is a common and complex disorder, especially in highly industrialized countries. The Framingham Heart Study reported the lifetime risk of hypertension to be approximately 90% for men and women. 1 According to the International Society of Hypertension, nearly 7.6 million deaths worldwide (13.5% of all deaths) are attributed to hypertension each year. 2 The substantial heritability (30%-60%) 3 of hypertension has prompted scientists to study its genetic underpinnings. To date, several largescale genome-wide association studies (GWASs) and meta-analyses on hypertension or blood pressure have been published. Although these studies have identified background Although many large-scale genome-wide association studies (GWASs) have been performed, only a few studies have successfully identified replicable, large-impact hypertension loci; even fewer studies have been done on Chinese subjects. Young-onset hypertension (YOH) is considered to be a more promising target disorder to investigate than late-onset hypertension because of its stronger genetic component.
some hypertension-associated loci, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] most of them do not replicate among one another (for gene list, please see Supplementary Table S1 ).
These GWASs were conducted mostly in populations of European descent. Previous Asian studies were carried out primarily in Japanese and Korean populations, and the findings may or may not be applicable to Han Chinese populations. In addition, most of the previous hypertension studies have involved relatively older patients. Environmental factors may contribute significantly to this type of hypertension. It has been suggested that young-onset hypertension (YOH) may be more linked with genetic components. 23, 24 Our previous linkage, candidate gene, and genome-wide association studies have successfully identified multiple susceptibility genes and chromosome regions in Han Chinese YOH. 8, [24] [25] [26] [27] Most GWASs have taken a single-locus analysis strategy with each single nucleotide polymorphism (SNP) tested individually. However, this method does not have enough statistical power to detect small-effect SNPs. Multilocus association tests, which integrate genetic information, such as the P value combination method, are an alternative method to increase the statistical power to detect the susceptibility genes. This study adopted a 3-stage GWAS. We used multilocus association tests to identify regions of interest and a gene expression association test to select genes with differential expression, and we confirmed our findings with an independent set of samples. Moreover, 2 additional replication analyses for this study were performed using genotype data from the other Han Chinese population in the Hong Kong Hypertension Study (HKHS) 28 and a white population in the Wellcome Trust Case-Control Consortium Hypertension Study (WTCCCHS). 22 
METHODS

Study design and samples
We performed a 3-stage case-control association scan. The regular 1st-stage GWAS was used to find potential susceptibility regions or genes. Then, a 2nd-stage gene expression study using the same samples was used to find differentially expressed genes among those implicated in the 1st stage. The 3rd stage consisted of a confirmatory association study with an independent set of samples. Our case subjects were 1,023 YOH patients recruited as part of the Academia Sinica Multi-Centered Young-Onset Hypertension Genetic Study. 8 These patients were aged >20 years and first diagnosed with hypertension before age 51 years.
Among these patients, only 992 patients had remaining blood DNA materials and were selected for this study. We arbitrarily divided these patients into two subsamples: 400 patients (272 men and 128 women) as the 1st-and 2nd-stage case subjects and the remaining 592 patients (411 men and 181 women) as the 3rd-stage case subjects. For study control subjects, we adopted a 1-to-1 match strategy to select an equal number of age-(±5 years) and sex-matched control subjects. The criteria for sample inclusion/exclusion are described in the Supplementary Methods.
The 400 healthy subjects for the 1st-and 2nd-stage controls were selected from the Taiwan Han Chinese Cell and Genome Bank. 29 The 592 healthy subjects for the 3 rd -stage controls were selected from 2 resources: 550 individuals were selected from the Cardiovascular Disease Risk Factor Two-Township Study in Taiwan 30 and 42 individuals were selected from the Nutrition and Health survey in Taiwan. 31 (See the Supplementary Methods for the power calculation and the population admixture test.)
For the gene expression association study, we collaborated with the Bioresource Collection and Research Center (Taiwan) and the Phalanx Biotech (Taiwan) to generate whole-genome gene expression data from lymphoblast cell lines (LCLs) established from the 400 case-control pairs of the 1st stage.
We used LCLs to study expression because the target tissue of essential hypertension is unclear and LCLs are accessible. Human LCLs are gaining increased popularity as a research tool for studying genome-wide individual differences in transcriptomes. 32, 33 In the replication analysis, data from another Han Chinese population (HKHS) 28 and a white population (WTCCCHS) 22 were used. The HKHS used a family-based study design, which involved 111 families with a total of 315 individuals, including 37 affected sibling pairs and 195 discordant sibling pairs. The WTCCCHS involved 1,999 patients with hypertension and 3,004 normal control subjects consisting of 1,504 samples from the 1958 British Birth Cohort and 1,500 samples from the UK Blood Service Control Group.
Genotyping
In the 1st stage, samples from 400 case-control pairs were genotyped with the Illumina HumanHap550 (Illumina, San Diego, CA), which contains 560,184 tag SNPs. In the 3rd stage, the SNPs that had been identified in the 1st stage and verified by the expression study in the 2nd stage were genotyped. This genotyping was accomplished using the Sequenom iPLEX assay (Sequenom, San Diego, CA).
Information on genotyping call rate, Hardy-Weinberg equilibrium, and minor allele frequency was used to evaluate genotyping quality. SNPs were excluded if (i) the genotyping call rate was <0.95, (ii) the minor allele frequency was <0.01, or (iii) the SNP deviated from Hardy-Weinberg equilibrium with a -log 10 (P values adjusted for False Discovery Rate (pFDR)) >3. Finally, 497,849 SNPs were analyzed in this study.
Samples in the HKHS were genotyped with the Illumina HumanHap 610, which contains 620,901 tag SNPs. Samples in the WTCCCHS were genotyped with the Affymetrix Human Mapping 500K (Affymetrix, San Diego, CA), which provides 500,568 SNPs.
Gene expression experiment
In the 2nd stage, lymphoblast cell lines 32 with RNA integrity number >7, prepared for 253 case subjects and 299 control subjects from the original 400 pairs, were cultured to measure the gene expression profile. Human One Array 5.1 (Phalanx Biotech, Hsinchu city, Taiwan) was used to measure the gene expression profiles.
Statistical methods
First, we performed genome-wide single-locus association tests using exact conditional logistic regressions (CLR), 34 where a dichotomous disease status of YOH was regressed on SNP genotypes on either a nominal genotype scale (i.e., AA, AB, and BB) or an ordinal genotype coding scale (i.e., 0, 1, and 2 of allele A). Genetic effects of SNPs were examined using 1 million Monte Carlo samples generated from a hybrid network and Monte Carlo algorithm 35 by the LOGISTIC procedure of SAS software (SAS Institute, Cary, NC). Because body mass index is a potential confounder of blood pressure (P < 0.0001) (Supplementary Table S1 ), it was adjusted in all of the analyses.
Second, we performed genome-wide multi-locus association tests using a truncated product P value procedure 36 with the sliding-window procedure to scan the human genome chromosome by chromosome. In these tests, multiple moving window sizes of 3, 5, 7, and 9 SNPs were used, and the P values were obtained from the previous single-locus tests. The analysis was carried out using the PSMOOTH procedure of the SAS software.
To control linkage disequilibrium as a potential confounder in the multi-locus tests, permutation tests were performed to remove the potentially inflated significance in our genome-wide P value combination tests. 37 We permuted for disease status and genotype, respectively. A total of 10,000 permutations each were performed for calculating empirical P values. The matched relationship between case patients and control subjects were maintained in the process. Because the results for both sets of permutations were very similar, only the one on disease status was shown (see Supplementary Table S2 for the results of genotype permutation tests).
Third, in the 2nd stage, a gene expression association test was performed to remove those genes that were not differentially expressed between case patients and control subjects. Quantile normalization 38 was applied to normalize gene expression levels. With adjustment for age, sex, and body mass index, BRB-Arraytools (developed by Dr Richard Simon and the BRB-ArrayTools Development Team) was performed to analyze the normalized data with 10,000 permutations to identify the differentially expressed ones among the identified genes. In the 2nd stage, only the SNPs with at least 1 gene located within ±50 kb of the flanking regions were verified by gene expression study.
Fourth, the confirmatory association study was carried out, using either independent data of the 529 case-control matched pairs or joint data with 929 case-control matched pairs. Genotyping quality control procedures and association tests were identical to those used in the 1st stage.
Multiple testing corrections were carried out to avoid the false-positive results. These corrections were done by using the false discovery rate (FDR) method 39 in all stages of analyses. In the 1st stage, SNP septets with -log 10 (pFDR) > 3 were considered significant for marker-trait associations. 8 After the nonsignificant SNP septets were removed, large numbers of SNP septets remained. To focus on the most potential genes, only the genes located in the 20 topranked SNP septets were selected to test their gene expressions in the 2nd stage, and in the 3rd stage confirmatory association study was carried for those differentially expressed.
Moreover, we validated our results using 2 population samples (HKHS and WTCCCHS). First, we related genotype data of identical SNPs we identified with 4 hypertension-related phenotypes from the HKHS. The four phenotypes were as follows: (i) dichotomous disease status, (ii) quantitative systolic blood pressure, (iii) quantitative diastolic blood pressure, and (iv) quantitative mean arterial pressure. A single-locus siblingbased transmission disequilibrium test (DFAM-sibTDT) 40 was applied to examine the genetic association of the phenotypes with the SNPs. Quantitative family-based association tests, 41 including within-family test and total association test, were applied to examine the genetic association of systolic blood pressure, diastolic blood pressure, and mean arterial pressure with SNPs (total test is designed to extract all association information from a family-based sample, controlling for relatedness). All analyses were done with PLINK. Because WTCCCHS used the Affymatrix 6.0 platform, the Affymatrix SNPs located in the regions we defined were examined with hypertension status by the single-locus test. After the P values were obtained by single-locus tests from HKHS and WTCCCHS, we used the same P value combination methods previously described for the 1st-stage GWAS.
RESULTS
First-stage GWAS
For the single-locus GWAS, P values from all single SNPs were obtained for the CLR-NOMINAL (P = 0.47 to 1.11 × 10 -7 ) and for the CLR-ORDINAL (P = 0.51 to 2.65 × 10 -8 ) analyses, for which body mass index was adjusted in the model. After FDR correction, there was no SNP significantly associated with YOH.
We further examined the effects of multiple SNPs on YOH by P value combination analysis with sliding windows of 3, 5, 7, and 9 SNPs. Because the analyses of different window sizes identified similar association regions, here we show only the results of window size 7.
A total of 840 and 1,607 SNP septets reached P value threshold (-log 10 (pFDR) > 3) in the CLR-NOMINAL and CLR-ORDINAL, respectively (Supplementary Figure S1) . In addition, 453 SNP septets (approximately 3,000 SNPs) reached the P value threshold in both the CLR-NOMINAL and CLR-ORDINAL. Only the 20 top-ranked SNP septets (pFDR < 3.16 × 10 -7 ) were selected for further expression study. Six septets are not in the ±50 Kbp region of any known genes. Therefore, we focused on the 14 septets that flanked 22 genes (Table 1 and Supplementary Figure  S2 ). Information about minor allele frequency, physical position, and linkage disequilibrium (LD) of these SNPs are shown in Supplementary Table S2 and Supplementary Figure S3 .
Second-stage gene expression association study
There may be >1 gene located in each septet region that we selected in the 1st stage. We carried out a gene expression association study to examine which genes' expression Table 2) .
Third-stage confirmatory association study
To confirm the multilocus GWAS results of the 4 differentially expressed genes, an independent set of samples with 529 case-control pairs was genotyped for the SNPs flanking the observed genes. The SNP septet near the GSN gene on chromosome 9 (rs12340264-rs3747846-rs17086-rs2416829-rs2572854-rs2196311-rs306777) was significantly associated with YOH (pFDR = 0.028) ( Table 3 ). The septet near the LARS gene on chromosome 5 (rs4913057-rs758037-rs168712-rs6580404-rs2962519-rs248780-rs248779) was also associated with YOH, but the direction of association was completely reversed. Therefore, in the joint analysis with 929 case-control matched pairs, LARS is not associated with YOH. The SNP septets in C1orf135, GSN, and ACTN4 were all significantly associated with YOH after the FDR adjustment (Table 4) .
Replication analysis
In the HKHS replication analysis, among the 4 regions we identified, ACTN4 and LARS regions were significantly associated with dichotomous disease status (pFDR = 0.012) and systolic blood pressure (pFDR = 0.022), respectively (Supplementary Table S3 ). Among the 4 regions, ACTN4-hypertension association was not only observed in our study and HKHS, but it was also seen in the WTCCCHS (pFDR = 6.63 × 10 -5 ) (Supplementary Table S4 ). The results are summarized in Supplementary Table S5 .
DISCUSSION
To date, there have been more than a dozen GWASs published on hypertension or blood pressure traits, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 42 including 1 previous small-scale study and a recent gene-based study published by our group. However, there was very little repetition in the genes discovered across studies, with the exceptions of CYP17A1, SH2B3, CDH13, and WWOX (see Supplementary Table S1 ). Given the genetic differences noted between the European and Asian populations, our GWAS is unique in its focus on a young Han Chinese population and in its finding of several previously unreported susceptibility genes.
Most hypertension/blood pressure GWASs previously performed recruited patients aged 20-70 years, in contrast with our study, which recruited YOH patients with an onset time before age 51 years. Although it is arguable whether one should use age 40 or 50 years as the onset cutoff for YOH, 43 we did identify 4 genes, including 1 additional genes (ACTN4, LARS), compared with our previous genebased study. 42 Among the 4, associations with ACTN4 and LARS were also observed using data from the HKHS and the WTCCCHS. The potential biological significances of the 4 genes are discussed below.
The most significant septets identified in our study are rs732135-rs755690 and rs752067-rs973009, which are located on chromosome 19q13. These two septets are both located in the intron 1 of ACTN4. ACTN4 has been associated with cortical renal glomerulopathies, abnormal kidney physiology, small kidney, proteinuria, and abnormal blood urea nitrogen level. 44 ACTN4 was also found in our previous gene-based YOH association study. 42 This study shows that the sliding window approach narrows the susceptible region to intron 1.
The SNP septet rs4913057-rs248779 is approximately 42 Kbp upstream of LARS. LARS is located on chromosome 5q32, encoding the cytosolic leucyl-tRNA synthetase. The encoded enzyme catalyzes the ATP-dependent ligation of L-leucine to tRNA. Although the SNP septets in LARS were detected again by the independent samples of our study and that of the HKHS, they were not detected in the joint analysis. This discrepancy was caused by the different direction of the associations between the population in the 1st stage and the 2nd stage. Because the results have been inconsistent, further investigation is still required.
The septet rs12340264-rs306777 is approximately 30.4Kbp downstream from GSN, which is located on chromosome 9q34. Some animal experiments showed that GSN-deficient mice exhibit delayed neutrophil migration in response to inflammatory stimuli and have prolonged bleeding times, which have been attributed to platelet morphologic abnormalities. 45 Although the GSN gene was consistently found in stages 1, 2, and 3, this gene cannot be verified by the data from the HKHS and that of the Only the genes that reached P < 0.05 are shown. Abbreviations: CHR, chromosome; FDR, false discovery rate. * pFDR ≤ 5 × 10 -2 . WTCCCHS, which implies that this gene may be specific to the Taiwanese population.
The P value combination test with sliding windows has some merits over the conventional single SNP association test. Because this method combines genetic contributions of multiple SNPs in a region, the test power may be increased, and the effect of locus heterogeneity of an influential region may be alleviated.
However, it is possible that a significant SNP in LD with neighboring SNPs may artificially inflate the significance score of a septet in the initial sliding window GWAS. To account for the dependency of P values, permutation tests were performed to remove the potential inflated significance in our study. LD structure is maintained in the permutation data because only disease statuses of samples are randomly permuted under a null distribution. This permutation procedure has been broadly used for handling P value dependency. 37 The gene-based association test that we used in our previous study 42 shares the merit of combining genetic contributions of multiple SNPs, but gene-based association test only combines the P-values of SNPs within a gene region. However, it neglects the intergenic regions, which may also regulate gene expression. 46 Some studies have reported that a SNP within 100 Kbp downstream or upstream of the gene may modulate expression level. 47 Using P value combination test with sliding widow may help us to find those intergenic regions, such as the loci near the GSN and LARS we identified. Integrating the gene-based and the sliding window P value combination tests can provide a more comprehensive detection of the susceptibility variants of complex diseases because they are complementary to each other.
Our study is not free of shortcomings. Because of a relatively small sample size, some small-effect YOH loci may have been overlooked in our study. For future meta-analyses, our information on all P values of SNP and gene expression data are available for download from the website http:// pan.ibms.sinica.edu.tw/hypertension/data2. In addition, we used LCLs to study gene expression profiles because of the nature of this human study. Some studies have demonstrated that approximately 30% of gene expression profiles are shared among tissues, whereas 29% are exclusively tissue specific. 32, 48 We may miss some tissue-specific signals, but the finding should be valid. Besides, LCL presents advantages in its biological validity, tractability, and availability and the reduced influence of environmental conditions. 49 In conclusion, by using a sliding window approach coupled with the P value combination tests, we identified previously a unknown YOH locus near intron 1 of the ACTN4 gene and loci upstream or downstream of GSN and LARS in Han Chinese. All of these loci were validated by our gene expression and the independent sample study. Furthermore, the ACTN4 locus and LARS locus were also associated with the respective blood pressure or hypertension traits by the HKHS or WTCCCHS.
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